

Clinical trials of CDK (cyclin-dependent kinase) inhibitor for lung cancer (metastatic) in all type of patients

TrialResults-center www.trialresultscenter.org

1 CDK4 and CDK6 selective CDK inhibitor

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|-------------------------------|
| abemaciclib vs erlotinib | | | |
| JUNIPER , 2018 [NCT02152631] n=453 follow-up: | 200 mg of abemaciclib orally twice daily versus 150 mg of erlotinib | patients with stage IV NSCLC with a detectable KRAS mutation who progressed after platinum-based chemotherapy and who may have received 1 additional systemic therapy | Parallel groups open-label |

References

JUNIPER, 2018:

Goldman JW, Shi P, Reck M, Paz-Ares L, Koustenis A, Hurt KC Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. Clin Lung Cancer 2016;17:80-4 [26432508]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.